Salarius Pharmaceuticals (SLRX) Competitors $5.45 +0.16 (+3.02%) Closing price 04:00 PM EasternExtended Trading$5.24 -0.21 (-3.76%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. ALBT, ERNA, INAB, APRE, DWTX, ADXN, APM, KPRX, PCSA, and RNAZShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Avalon GloboCare (ALBT), Ernexa Therapeutics (ERNA), IN8bio (INAB), Aprea Therapeutics (APRE), Dogwood Therapeutics (DWTX), Addex Therapeutics (ADXN), Aptorum Group (APM), Kiora Pharmaceuticals (KPRX), Heatwurx (PCSA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Its Competitors Avalon GloboCare Ernexa Therapeutics IN8bio Aprea Therapeutics Dogwood Therapeutics Addex Therapeutics Aptorum Group Kiora Pharmaceuticals Heatwurx TransCode Therapeutics Salarius Pharmaceuticals (NASDAQ:SLRX) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership. Is SLRX or ALBT more profitable? Salarius Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Avalon GloboCare's return on equity of 0.00% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -556.47% -192.35% Avalon GloboCare -1,451.94%N/A -75.12% Does the media refer more to SLRX or ALBT? In the previous week, Salarius Pharmaceuticals had 3 more articles in the media than Avalon GloboCare. MarketBeat recorded 6 mentions for Salarius Pharmaceuticals and 3 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.66 beat Salarius Pharmaceuticals' score of 0.48 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Salarius Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalon GloboCare 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, SLRX or ALBT? Salarius Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Do institutionals & insiders believe in SLRX or ALBT? 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 1.2% of Salarius Pharmaceuticals shares are held by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, SLRX or ALBT? Salarius Pharmaceuticals has higher earnings, but lower revenue than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$5.58M-$43.48-0.13Avalon GloboCare$1.33M7.51-$7.90M-$19.96-0.13 SummarySalarius Pharmaceuticals and Avalon GloboCare tied by winning 6 of the 12 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.78M$2.83B$5.75B$10.27BDividend YieldN/A57.24%5.72%4.60%P/E Ratio-0.1323.2874.9226.41Price / SalesN/A526.28457.0188.61Price / CashN/A27.5625.8129.91Price / Book0.385.4013.256.28Net Income-$5.58M$32.95M$3.29B$270.38M7 Day Performance17.20%0.20%0.47%2.70%1 Month Performance-21.32%4.10%4.59%5.99%1 Year Performance-76.71%-2.91%73.41%25.94% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.2944 of 5 stars$5.45+3.0%N/A-77.4%$2.78MN/A-0.1320Short Interest ↑Gap UpHigh Trading VolumeALBTAvalon GloboCare1.1135 of 5 stars$2.51+6.4%N/A-25.3%$9.64M$1.33M-0.135News CoverageAnalyst DowngradeShort Interest ↑ERNAErnexa Therapeutics0.9803 of 5 stars$1.26+1.2%N/A-94.3%$9.63M$580K-0.1510INABIN8bio3.4931 of 5 stars$2.06-4.6%$180.00+8,637.9%-77.9%$9.35MN/A-0.2320Positive NewsShort Interest ↓APREAprea Therapeutics2.7805 of 5 stars$1.60-0.4%$15.50+866.3%-51.0%$9.35M$1.50M-0.697Short Interest ↑Gap DownDWTXDogwood Therapeutics2.1012 of 5 stars$4.87-0.6%$10.00+105.3%N/A$9.31MN/A-0.265Gap DownADXNAddex Therapeutics3.1786 of 5 stars$8.70+7.5%$30.00+245.0%+11.0%$9.22M$460K-25.5830Positive NewsGap DownAPMAptorum Group0.7651 of 5 stars$1.72+0.6%N/A-31.3%$9.20M$430K0.0030Short Interest ↑KPRXKiora Pharmaceuticals2.6072 of 5 stars$2.65-1.7%$10.00+278.1%-27.9%$9.07M$16.02M-0.9110Short Interest ↑PCSAHeatwurx3.6891 of 5 stars$0.18-3.0%$1.00+465.0%-85.9%$8.91MN/A-0.0820Positive NewsShort Interest ↓Gap UpRNAZTransCode Therapeutics2.3644 of 5 stars$10.73-1.2%$280.00+2,509.5%-99.9%$8.91MN/A0.009Gap Up Related Companies and Tools Related Companies ALBT Competitors ERNA Competitors INAB Competitors APRE Competitors DWTX Competitors ADXN Competitors APM Competitors KPRX Competitors PCSA Competitors RNAZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
